$KBLB

Kraig Biocraft Laboratories (KBLB) launched a research program to improve spider silk production in genetically engineered silkworms through targeted nutritional supplements. The company aims to enhance protein production and silk fiber characteristics, complementing its genetic engineering efforts. Early results are encouraging, but no quantitative data or timeline has been disclosed.

Kraig Biocraft Laboratories (KBLB) began a program to develop new yarns using its spider silk and sent samples to a firm collaborating with aerospace manufacturers. This is an early-to-mid stage commercialization effort following an initial custom yarn sale.

Kraig Biocraft Laboratories (KBLB) applied to expand its Prodigy Silk subsidiary's investment licence to boost spider silk production capacity. The company reported record output, with August production exceeding 30% more than June's 2.5 metric tons. Kraig shipped its first custom spider silk yarn for performance sportswear, marking progress toward commercial applications. Key uncertainties include investment approvals, funding, and converting customer interest into recurring orders.

Kraig Biocraft Laboratories announced all three production centers are operational and commercial deliveries have begun, including a shipment to a sportswear brand. This marks initial commercialization after years of development, with potential catalysts being order sizes, contracts, and revenue data.